Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
ZacksInvestors who own AbbVie’s (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira’s patent cliff, quite well and looks set to return to robust growth next year.